| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 6, 2026, by and among Abeona Therapeutics Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement... |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Abeona Therapeutics Inc. is furnishing in this Current Report on Form 8-K an updated investor presentation (the “Investor Presentation”) that it expects to use, either in whole or in part, on September 15, 2026 at the H.C. Wainwright 28t... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders of Abeona Therapeutics Inc. (the “Company”) was held virtually on June 12, 2026, at 9:00 a.m., Eastern Time. The following matters were acted upon: |
| 12 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) effective immediately. In connection with his resignation, Mr. Amoroso also resigned from the Nomi... |
| 10 Jun 2026 |
8-K: Regulation FD Disclosure
Abeona Therapeutics Inc. is furnishing in this Current Report on Form 8-K an updated investor presentation (the “Investor Presentation”) that it expects to use, either in whole or in part, in connection with presentations to investors, a... |
| 04 Jun 2026 |
8-K: Other Events
On June 3, 2026, Abeona Therapeutics Inc. (the “Company”) participated in a pre-Investigational New Drug application (“Pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding ABO-701, a recently licensed radically ... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
-QTC network expands to six sites, with two new additions on the East Coast - |
| 07 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
CLEVELAND, April 7, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Cha... |
| 20 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
On March 16, 2026, the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) approved the adoption of the Third Amended and Restated Bylaws of the Company, effective as of March 16, 2026 (the “New Bylaws”), which a... |
| 17 Mar 2026 |
8-K: Results of Operations and Financial Condition
- First ZEVASKYN® commercial patient treatment completed in December - |
| 09 Mar 2026 |
8-K: Other Events
CLEVELAND, March 9, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therap... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - |
| 18 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ... |
| 02 Jul 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more
Cash resources totaled approximately $225 million as of June 30, 2025 |
| 19 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders of Abeona Therapeutics Inc. (the “Company”) was held virtually on May 19, 2025 at 9:00 a.m., Eastern Time. The following matters were acted upon: |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dyst... |
| 12 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
CLEVELAND, May 12, 2025 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 milli... |
Loading...